Lv6
2988 积分 2024-06-21 加入
Structural Preferences and ADMET Regulation of Fluorinated Small-Molecule Drugs
13天前
已完结
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma
18天前
已完结
Design of Potent and Selective BCL6 Transcriptional Chemical Inducers of Proximity through Linker Optimization
20天前
已完结
Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors
20天前
已完结
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
1个月前
已完结
Discovery of Novel CBP/p300 and BRD4 Dual-target PROTACs with Potent Antitumor Activity in Prostate Cancer
1个月前
已完结
Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma
1个月前
已关闭
Discovery of Small-Molecule GLP-1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron
2个月前
已完结
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
2个月前
已完结
RIPTACs: A groundbreaking approach to drug discovery
4个月前
已完结
皖公网安备34019202002308
